National Institute on Drug Abuse; Notice of Meeting, 70201-70202 [2019-27512]
Download as PDF
<![CDATA[
70201
Federal Register / Vol. 84, No. 245 / Friday, December 20, 2019 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
Short-Term Research Experience for Underrepresented Persons (STEP–UP) Application.
STEP–UP Student Feedback Form .....................
Diversity Summer Research Training Program
(DSRTP) Feedback Form.
Network of Minority Health Research Investigators (NMRI) Enrollment Form.
NMRI Evaluation Form .........................................
NMRI Survey Form ...............................................
NMRI Mentor-Mentee Agreement Form ...............
NIH/National Medical Association (NMA) Academic Career Fellow Travel Awards Application.
NIH/NMA Feedback Form ....................................
NIH/National Hispanic Medical Association
(NHMA) Academic Career Fellow Travel
Awards Application.
NIH/NHMA Feedback Form ..................................
Total ...............................................................
Dated: December 12, 2019.
Starsky Cheng,
NIDDK Project Clearance Liaison, Office of
Management and Policy Analysis, National
Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health.
[FR Doc. 2019–27514 Filed 12–19–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; ZAI1 FDS M M1, January
30–31, 2020, Targeted Prevention for
Tickborne Diseases (R01—Clinical Trials Not
Allowed).
Date: January 30–31, 2020.
VerDate Sep<11>2014
18:30 Dec 19, 2019
Number of
respondents
Type of respondent
Jkt 250001
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total annual
burden hours
Individuals/Households
2,000
1
45/60
1,500
Individuals/Households
Individuals/Households
200
14
1
1
15/60
30/60
50
7
Private Sector ...............
200
1
15/60
50
Private
Private
Private
Private
...............
...............
...............
...............
120
800
100
200
1
1
1
1
30/60
30/60
30/60
20/60
60
400
50
67
Private Sector ...............
Private Sector ...............
40
200
1
1
30/60
20/60
20
67
Private Sector ...............
40
1
30/60
20
.......................................
........................
3,914
........................
2,291
Sector
Sector
Sector
Sector
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room #3E72A, National Institutes of Health,
National Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, MSC 9823,
Rockville, MD 20892–9823, (240) 669–5023,
fdesilva@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: December 16, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–27507 Filed 12–19–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council on Drug Abuse.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Drug Abuse.
Date: January 30, 2020.
Closed: 9:00 a.m. to 10:15 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC),
Conference Rooms C&D, 6001 Executive
Boulevard, Rockville, MD 20852.
Open: 10:30 a.m. to 4:30 p.m.
Agenda: This portion of the meeting will
be open to the public for announcements and
reports of administrative, legislative, and
program developments in the drug abuse
field.
Place: National Institutes of Health,
Neuroscience Center Building (NSC),
Conference Rooms C&D, 6001 Executive
Boulevard, Rockville, MD 20852.
Contact Person: Susan R.B. Weiss, Ph.D.,
Director, Division of Extramural Research,
Office of the Director, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, NSC, Room 5274, MSC 9591,
E:\FR\FM\20DEN1.SGM
20DEN1
70202
Federal Register / Vol. 84, No. 245 / Friday, December 20, 2019 / Notices
Rockville, MD 20892, 301–443–6487,
sweiss@nida.nih.gov.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
Information is also available on the
Institute’s/Center’s home page:
www.drugabuse.gov/NACDA/
NACDAHome.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: December 16, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–27512 Filed 12–19–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jbell on DSKJLSW7X2PROD with NOTICES
National Institute of Diabetes and
Digestive and Kidney Diseases, Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel HIV
PATHOGENESIS.
VerDate Sep<11>2014
18:30 Dec 19, 2019
Jkt 250001
Date: February 25, 2020.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Boulevard, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Elena Sanovich, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7351, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, (301) 594–8886,
sanoviche@mail.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel Pragmatic Research/
Natural Experiments.
Date: March 3, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites,
Conference Room Democracy, 6711
Democracy Boulevard Bethesda, MD 20817.
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
Division of Extramural Activities, NIDDK,
National Institutes of Health, Room 7353,
6707 Democracy Boulevard, Bethesda, MD
20892–2542, (301) 594–8898, barnardm@
extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel Digestive Diseases
Research Core Centers (P30).
Date: March 26–27, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, Conference
Room Montgomery 1&2, 7335 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Jian Yang, Ph.D., Scientific
Review Officer, Review Branch, Division of
Extramural Activities, NIDDK, National
Institutes of Health, Room 7111, 6707
Democracy Boulevard, Bethesda, MD 20892–
5452, (301) 594–7799, yangj@
extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: December 17, 2019.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–27513 Filed 12–19–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; TEP–6:
SBIR Contract Review Meeting.
Date: January 31, 2020.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W106, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Reed A. Graves, Ph.D.,
Scientific Review Officer, 9609 Medical
Center Drive, Room 7W106, Division of
Extramural Activities, Research Technology
and Contract Review Branch, National
Cancer Institute, NIH, Rockville, MD 20850,
240–276–6384, gravesr@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–4: NCI
Clinical and Translational R21 and Omnibus
R03.
Date: February 27–28, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Eduardo Emilio Chufan,
Ph.D., Scientific Review Officer, Research
Technology & Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W254, Bethesda, MD 20892,
240–276–7975, chufanee@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Outstanding Investigator Award.
Date: February 27–28, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Michael B. Small, Ph.D.,
Chief, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, 7 Floor, West Tower, Room
7W522, Bethesda, MD 20892–9750, 240–276–
6438, smallm@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; TEP–8:
SBIR Contract Review Meeting.
E:\FR\FM\20DEN1.SGM
20DEN1
]]>Agencies
[Federal Register Volume 84, Number 245 (Friday, December 20, 2019)]
[Notices]
[Pages 70201-70202]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-27512]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Council on Drug Abuse.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: January 30, 2020.
Closed: 9:00 a.m. to 10:15 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center
Building (NSC), Conference Rooms C&D, 6001 Executive Boulevard,
Rockville, MD 20852.
Open: 10:30 a.m. to 4:30 p.m.
Agenda: This portion of the meeting will be open to the public
for announcements and reports of administrative, legislative, and
program developments in the drug abuse field.
Place: National Institutes of Health, Neuroscience Center
Building (NSC), Conference Rooms C&D, 6001 Executive Boulevard,
Rockville, MD 20852.
Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of
Extramural Research, Office of the Director, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, NSC, Room 5274, MSC
9591,
[[Page 70202]]
Rockville, MD 20892, 301-443-6487, [email protected].
Any member of the public interested in presenting oral comments
to the committee may notify the Contact Person listed on this notice
at least 10 days in advance of the meeting. Interested individuals
and representatives of organizations may submit a letter of intent,
a brief description of the organization represented, and a short
description of the oral presentation. Only one representative of an
organization may be allowed to present oral comments and if accepted
by the committee, presentations may be limited to five minutes. Both
printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
committee by forwarding their statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: December 16, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-27512 Filed 12-19-19; 8:45 am]
BILLING CODE 4140-01-P
